linjc16/ctgov huggingface dataset:
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Official Title
-----------------
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: GIP-infusion
* Other: Sodium-chloride
* Other: GLP-2 infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasians over 18 years with type 1 diabetes (WHO criteria) Arginine test without rise in plasma C-peptide Normal blood Hemoglobin Informed consent Exclusion Criteria: Liver disease Diabetic nephropathy Treatment with medications unpausable for 12 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: B<br>GLP-2 infusion | Other: GLP-2 infusion<br> <br> |
| Placebo Comparator: C<br>Sodium-chloride infusion | Other: Sodium-chloride<br> <br> |
| Active Comparator: A<br>GIP-infusion | Other: GIP-infusion<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glucagon, Glucose-dependent Insulinotropic Polypeptide, Glucagon-Like peptide 2
Clinical Relevance of Typing HLA-DR7-DQ2

Study Overview
=================
Brief Summary
-----------------
Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.

Official Title
-----------------
Clinical Relevance of Typing HLA-DR7-DQ2

Conditions
-----------------
Celiac Disease Patients Following Recommendations of ESPGHAN, HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes

Intervention / Treatment
-----------------
* Other: There is not any intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of celiac disease following ESPGHAN recommendations HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes Exclusion Criteria: Patients who have not been diagnosed for celiac disease HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HLA-DR3-DQ2 patients<br>Patients with HLA-DR3-DQ2 haplotype | Other: There is not any intervention<br> <br> |
| HLA-DR7-DQ2 patients<br>Patients with HLA-DR7-DQ2 haplotype | Other: There is not any intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-tissue transglutaminase |  | Up to 1 month after diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Endomysium autoantibodies |  | Up to 1 month after diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Celiac disease, HLA-DQ2.2, HLA-DQ2.5, HLA-DR7-DQ2, HLA-DR3-DQ2
Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

Study Overview
=================
Brief Summary
-----------------
Within this study patient data are collected from different imaging and motion monitoring devices that will be used to develop and test strategies for image-guided adaptive radiotherapy in cervix cancer patients.

Official Title
-----------------
Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

Conditions
-----------------
Cervix Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological diagnosis of cervix cancer Prescription of radiation treatment to the primary cancer Exclusion Criteria: Prior radiation treatment to the pelvis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cervix cancer patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in therapeutic ratio |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Image guided adaptive radiotherapy
Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation

Study Overview
=================
Brief Summary
-----------------
Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock. Similarly to postcardiac surgery patients, heparin-induced thrombocytopenia (HIT) could represent the causative underlying mechanism. However, the epidemiology as well as related mortality regarding HIT and VA-ECMO remains largely unknown. The investigators aimed to define the prevalence and associated 90-day mortality of HIT diagnosed under VA-ECMO.This retrospective study included patients under VA-ECMO from 20 French centers between 2012 and 2016.

Official Title
-----------------
Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation

Conditions
-----------------
Heparin-induced Thrombocytopenia

Intervention / Treatment
-----------------
* Other: Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Patient hospitalized in intensive care for a cardiovascular failure requiring the setting up of an ECMO-VA ECMO-VA duration ≥ 3 days HIT confirmed by immunological tests Patient affiliated to a Social Security scheme Exclusion Criteria: Known antecedent of TIH prior to cannulation Pregnant woman ECMO-VA following cardiopulmonary arrest or septic shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death |  | 90 days after inclusion |
Urine pH as a Predictor of Diabetes

Study Overview
=================
Brief Summary
-----------------
Urine pH has been lately linked to insulin resistance. The early phase of Diabetes Mellitus involves insulin resistance. Thus, the investigators want to check if a simple cheap study like a urine analysis that can predict diabetes.

Official Title
-----------------
Urine pH as a Predictor of Diabetes

Conditions
-----------------
Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 Exclusion Criteria: diabetes CKD urine infection UTO bladder dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults, nondiabetics<br>adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of diabetes using a predicting formula |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, urine pH, insulin resistance, metabolic syndrome, development of diabetes
Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.

Official Title
-----------------
Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis, Relapsing-Remitting

Intervention / Treatment
-----------------
* Other: Intermittent Hypoxia
* Other: Sham Hypoxia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have relapsing-remitting MS Volitional ankle plantar flexion strength in at least one leg Are relapse free for 30 days Patient-Determined Disease Steps scale score between 3 and 5 (3=gait disability to 5=late cane, need cane to walk 25 feet) Exclusion Criteria: Currently taking antispasticity medications, Have cardiovascular or respiratory/pulmonary disorders, metabolic dysfunction, or prior diagnoses of obstructive sleep apnea Pregnant or nursing women (safety for developing fetus or infant is unknown) Cognitive concerns (must be able to consent to study, follow steps)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acute Intermittent Hypoxia<br>1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts | Other: Intermittent Hypoxia<br>* 1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.<br>|
| Sham Comparator: Sham Acute Intermittent Hypoxia<br>1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts. | Other: Sham Hypoxia<br>* 1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Voluntary Ankle Strength | Maximum isometric ankle plantar-flexion and dorsi-flexion torque using a Biodex | 60 minutes post-intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electromyogram activity | Plantar-flexor and Dorsi-flexor electromyogram activity | 60 minutes post-intervention | 
| Symbol Digit Modalities Test | The symbol-digit modalities test (SDMT) is a symbol substitution neuropsychological test that examines a person's attention and speed of processing | 60 minutes post-intervention |
Homeostatic Sleep Regulation in Older Persons

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the hypothesis that sleep homeostasis, also known as sleep pressure or sleep drive, is different in healthy older and younger individuals.

Detailed Description
-----------------
This was an inpatient study of healthy individuals to determine whether homeostatic sleep drive effects on sleep change with healthy aging. Sleep, performance, and mood were studied on individuals sleeping different lengths of time and during wake periods of different durations.

Official Title
-----------------
Homeostatic Sleep Regulation in Older Persons

Conditions
-----------------
Aging, Healthy

Intervention / Treatment
-----------------
* Behavioral: Amount of sleep and wake


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18-30 and 60-85 years Healthy Exclusion Criteria: Any medications Sleep Disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Amount of sleep and wake|4 groups with different patterns of sleep and wake|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Sleep Time |  | During inpatient study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Changes in sleep with aging
Response Inhibition in Tourette Syndrome

Study Overview
=================
Brief Summary
-----------------
Tics are the hallmark symptoms in Tourette Syndrome. Patients with Tourette Syndrome have difficulties controlling unwanted movements. The ability to control the motor system involves the pre-supplementary motor area (pre-SMA) in the brain. In this study, we will use Transcranial Magnetic Stimulation to modulate the pre-SMA and determine effect on the ability to stop an unwanted action in a behavior task (stop signal task).

Official Title
-----------------
Using Repetitive Transcranial Magnetic Stimulation to Modulate Response Inhibition in Tourette Syndrome

Conditions
-----------------
Tourette Syndrome

Intervention / Treatment
-----------------
* Device: Repetitive TMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tourette Syndrome Exclusion Criteria: Autism spectrum disorder Mood disorder Epilepsy Implanted medical device (e.g. pacemaker, shunt, pumps)

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Repetitive TMS<br>Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation | Device: Repetitive TMS<br>* Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stop Signal Reaction Time (SSRT) | SSRT measured from stop signal task performance | Immediately after Repetitive Transcranial Magnetic Stimulation |
Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

Study Overview
=================
Brief Summary
-----------------
Objective: A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects. Study Design: Randomized,single-dose,2-way crossover.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Metformin HCl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is at least 18 years old. Subject had no clinically significant abnormal lab values at the screening evaluation. Subject's drugs of abuse, Hepatitis B, Hepatitis C, and HIV screenings were negative or non-relative. Acceptable screening of ECG. Female subject's pregnancy test at screening is negative. Subject had no evidence of underlying disease at the pre-entry physical examination. Subject has given written consent to participate. Female subject has not received any injectable or implantable contraceptive for a period of six months preceding this study. Agreed to undergo at least a 14-day pre-dose washout. Beginning two weeks prior to dosing and throughout the study, female subject of childbearing potential agrees to utilize one of the following methods of contraception: Condom and topical spermicide Condom and diaphragm Intra-uterine device (I.U.D) Complete abstinence. Agree to abstain from consuming caffeine or alcohol for at least 48 hours. prior to study and throughout the blood collection periods. Exclusion Criteria: History of treatment for alcoholism, substance abuse, or drug abuse with in the past 24 months. History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness. History of GRD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease. History of treatment for asthma, hypoxemia, dehydration, sepsis, metabolic acidosis and congestive heart failure. Subject is pregnant or lactating. History of drug hyper sensitivity. Subject was treated with any investigational drug during the four weeks prior to initial dosing for the study. Subject smokes more then 15 cigarettes per day or uses tobacco products or currently uses nicotine products.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Metformin HCl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

Study Overview
=================
Brief Summary
-----------------
This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.

Official Title
-----------------
A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)

Conditions
-----------------
Absence Seizures

Intervention / Treatment
-----------------
* Drug: Levetiracetam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/female 4-17 years old having participated in study N162 or in study N163 suffering from typical absences with 3 Hz spike-wave discharges, with or without tonic-clonic seizures, in CAE or JAE expected reasonable benefit (efficacy and tolerability) of levetiracetam long term administration Exclusion Criteria: allergy/intolerance to pyrrolidine derivatives and/or excipients use of > 2 concomitant antiepileptic treatment or valproate, ethosuximide or lamotrigine

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Levetiracetam|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continue levetiracetam treatment after participation in the pilot-study N162 or in study N163; Assess long-term safety profile and efficacy of levetiracetam |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Levetiracetam, Keppra